Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,536 | 3 | 38.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,865 | 2 | 31.2% |
| Honoraria | $6,400 | 2 | 29.1% |
| Food and Beverage | $192.38 | 2 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,302 | 1 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $4,000 | 1 | $0 (2022) |
| CSL Behring | $3,400 | 1 | $0 (2021) |
| Pharmacosmos Therapeutics Inc. | $3,000 | 1 | $0 (2021) |
| GlaxoSmithKline, LLC. | $2,925 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,803 | 3 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $563.65 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,611 | 1 | AstraZeneca Pharmaceuticals LP ($1,611) |
| 2022 | $6,925 | 2 | Regeneron Pharmaceuticals, Inc. ($4,000) |
| 2021 | $6,964 | 3 | CSL Behring ($3,400) |
| 2019 | $192.38 | 2 | AstraZeneca Pharmaceuticals LP ($192.38) |
| 2018 | $6,302 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,302) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| Category: Respiratory | ||||||
| 11/22/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| 06/02/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/03/2021 | Boehringer Ingelheim International GmbH | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $563.65 | General |
| Category: RESPIRATORY | ||||||
| 05/27/2021 | Pharmacosmos Therapeutics Inc. | Monoferric (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Hematology | ||||||
| 03/24/2021 | CSL Behring | — | Honoraria | Cash or cash equivalent | $3,400.00 | General |
| 09/27/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $57.56 | General |
| 06/20/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $134.82 | General |
| 11/21/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6,301.50 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 156 | 228 | $71,962 | $24,075 |
| 2022 | 4 | 158 | 307 | $93,391 | $28,764 |
| 2021 | 2 | 65 | 137 | $53,487 | $16,918 |
| 2020 | 4 | 122 | 253 | $79,789 | $26,699 |
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 79 | $23,313 | $7,880 | 33.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 27 | 41 | $24,477 | $7,427 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 67 | $14,686 | $5,129 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 21 | 22 | $6,902 | $2,575 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 19 | $2,584 | $1,064 | 41.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 83 | 200 | $55,800 | $16,742 | 30.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 26 | 45 | $26,865 | $8,185 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 31 | $6,510 | $2,330 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 23 | 31 | $4,216 | $1,507 | 35.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 25 | 48 | $28,656 | $9,053 | 31.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 89 | $24,831 | $7,865 | 31.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 62 | 150 | $41,850 | $13,528 | 32.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 22 | 51 | $30,447 | $10,918 | 35.9% |
| 94003 | Ventilation assistance and management, hospital inpatient or observation | Facility | 2020 | 12 | 20 | $3,140 | $1,170 | 37.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 16 | $2,176 | $701.83 | 32.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 15 | 16 | $2,176 | $381.56 | 17.5% |
About Dr. Nirupama Putcha, MD
Dr. Nirupama Putcha, MD is a Internal Medicine healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932302312.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nirupama Putcha, MD has received a total of $21,994 in payments from pharmaceutical and medical device companies, with $1,611 received in 2024. These payments were reported across 9 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($8,536).
As a Medicare-enrolled provider, Putcha has provided services to 501 Medicare beneficiaries, totaling 925 services with total Medicare billing of $96,455. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Pulmonary Disease
- Location Baltimore, MD
- Active Since 06/06/2007
- Last Updated 12/03/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1932302312
Products in Payments
- STIOLTO (Drug) $6,302
- DUPIXENT (Biological) $4,000
- Monoferric (Drug) $3,000
- TEZSPIRE (Biological) $1,611
- STIOLTO RESPIMAT (Drug) $563.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Baltimore
Dr. Shawn Kwatra, M.d, M.D
Internal Medicine — Payments: $978,358
Dr. Aloke Finn, Md, MD
Internal Medicine — Payments: $742,722
David Sidransky, M.d, M.D
Internal Medicine — Payments: $519,965
Dr. Shawn Dhillon, M.d, M.D
Internal Medicine — Payments: $495,197
Mark Levis, M.d, M.D
Internal Medicine — Payments: $450,553
Mark Sulkowski, M.d, M.D
Internal Medicine — Payments: $397,288